Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, it is hereby informed that the Officials of Supriya Lifescience Limited ('Company') had interacted with institutional investors/analysts on November 23, 2022 via video conference. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on November 22, 2022 via in person meeting. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby enclose the transcript of the Earnings call held on Friday, November 11, 2022 at 4.00 P.M. IST to discuss operational and financial performance of the Company for the quarter and half year ended September 30, 2022. Supriya Lifescience Ltd - 543434 - Disclosure Of Related Party Transactions Pursuant To Regulation 23 (9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of Related Party Transactions for the half year ended September 30, 2022. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Newspaper Publication
With reference to the above captioned subject, please find enclosed newspaper advertisement published in Financial Express and Loksatta on Saturday, November 12, 2022, containing extract of Unaudited Financial Results for the quarter and six months ended September 30, 2022. Supriya Lifescience Ltd - 543434 - Statement Of Deviation Or Variation In The Use Of Proceeds Of The Fresh Issue Of The Initial Public Offer Of The Company
Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended September 30, 2022 in the prescribed format. Further, we hereby confirm that there is no deviation or variation in the utilisation of IPO proceeds from the objects stated in the prospectus dated December 21, 2021. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by ICICI Bank Limited, Monitoring Agency, for the quarter ended September 30, 2022 in respect of utilization of proceeds of the of the fresh issue of the IPO of the Company. Supriya Lifescience Ltd - 543434 - Audio Recording Of Earnings Call
In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the audio recording of the Company''s Earnings Call held today (i.e., November 11, 2022) regarding discussion on operational and financial performance for the Second Quarter of FY 2022-2023 (Q2) is available on the Company''s website. The recording can be accessed from the link given below: https://supriyalifescience.com/investor-relation/financial/earning-call-recordings/ Supriya Lifescience Ltd - 543434 - Unaudited Financial Results For The Quarter And Six Months Ended September 30, 2022 (Revised)
We hereby enclose the following: 1. Copy of the Revised Unaudited Financial Results of the Company for the quarter and six months ended September 30, 2022 along with the Limited Review report issued by Statutory Auditor; Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation. You are requested to kindly take the same on record.